Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam versus ibuprofen for post-endodontic pain
IRCT20141209020258N109Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of meloxicam and ibuprofen in irreversible pulpitis (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Pain. Started Jan 2019; status: completed.
02
Drugs
meloxicamibuprofen
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on IRCT20141209020258N109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N109.